← back to search

Sheri Skerget

Arizona State University · US
Area of research
Hematology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Medicine, Multiple myeloma, Internal medicine, Biology, Antigen, and Refractory (planetary science).
h-index
citations
377
works
10
NIH funding
primary concept
email

Recent publications

Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma
Nature Medicine 2026cited by 2position: middledoi
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
The Lancet Haematology 2025cited by 72position: middledoi
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study
Blood 2025cited by 10position: middledoi
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1
Blood Advances 2025cited by 6position: middledoi
Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers
Blood 2025cited by 3position: middledoi
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
Nature Genetics 2024cited by 70position: firstdoi
Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
Blood 2024cited by 58position: middledoi
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
Blood Advances 2023cited by 73position: middledoi
Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study
Blood 2023cited by 44position: middledoi
Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment
Leukemia Research 2021cited by 39position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Leo Rasche · Universitätsklinikum Würzburg3 papers (2023–2025) · 3 papers (2023–2024)David Jung · University of South Carolina2 papers (2024–2025)Sacha Benaoudia · Université Claude Bernard Lyon 12 papers (2024–2025)Mansour Poorebrahim · Heidelberg University2 papers (2024–2025)Brandi Hilder · Johnson & Johnson (United States)2 papers (2023–2025) · 2 papers (2023–2025)Tara Masterson · Johnson & Johnson (United States)2 papers (2023–2025)Niels W.C.J. van de Donk · National Cancer Center2 papers (2023–2025)Sungwoo Ahn · Ontario Institute for Cancer Research2 papers (2024–2025)Holly Lee · Ontario Institute for Cancer Research2 papers (2024–2025) · 2 papers (2023–2025)Carolina Schinke · University of Arkansas for Medical Sciences2 papers (2023–2025)Diana Cortés‐Selva · Johnson & Johnson (United States)2 papers (2023–2025)Noémie Leblay · University of Calgary2 papers (2024–2025)Raluca Verona · Johnson & Johnson (United States)2 papers (2023–2025)Paola Neri · Ontario Institute for Cancer Research2 papers (2024–2025)Nizar J. Bahlis · University of Calgary2 papers (2024–2025)Deeksha Vishwamitra · University of Houston2 papers (2025–2025)Francesco Maura · Palmetto General Hospital2 papers (2024–2025)